Medpace Faces Securities Fraud Class Action Over Alleged Cancellation Rate Understatement; Lead Plaintiff Deadline June 8
MEDP sits 51% above its 52-week low of $287.17.
Summary
A class action lawsuit has been filed against Medpace Holdings and its executives for alleged securities fraud. The lawsuit claims the company understated Q4 2025 cancellation rates and overstated its book-to-bill ratio, which led to a 16% stock drop on February 9, 2026. This follows a previous news report on May 12, 2026, about a securities fraud class action, with this notification from Bleichmar Fonti & Auld LLP providing specific details and a lead plaintiff deadline. The legal action represents a significant ongoing risk for the company and its management due to potential liabilities. Investors have until June 8, 2026, to apply to be lead plaintiff in the case.
At the time of this announcement, MEDP was trading at $432.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $287.17 to $628.92. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.